Update on medications with adverse skeletal effects.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21389249.
- Also identified by DOI 10.4065/mcp.2010.0636 and PMC identifier 3068894.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients rely on their primary care physician to manage multiple, often chronic medical conditions that require prescription medications. Balancing the risk to benefit of treatments can be challenging and requires that the primary care physician stay abreast of new information regarding risks and benefits. The number of medications with reported adverse effects on skeletal health is expanding. This review focuses on medications recently added to the list of "bad to the bone" drugs and on recent advances in management of glucocorticoid-induced osteoporosis. A practical approach to assessing and managing the skeletal risks is outlined.
Medical subject headings
- Bone and Bones
- Osteoporosis